Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | 44 |
| Expenses | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | 23 |
| Operating Profit | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | 21 |
| OPM % | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | 48% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | 15 |
| Tax % | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | 27% |
| Net Profit | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | 11 |
| EPS in Rs | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 148 | 170 | 151 | 166 | 174 |
| Expenses | 27 | 30 | 33 | 34 | 53 | 50 | 57 | 75 | 91 | 82 | 89 | 91 |
| Operating Profit | 6 | 6 | 6 | 7 | 32 | 40 | 58 | 74 | 79 | 69 | 76 | 82 |
| OPM % | 19% | 17% | 16% | 18% | 37% | 45% | 51% | 50% | 46% | 46% | 46% | 47% |
| Other Income | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 7 | 4 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 5 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 13 | 15 |
| Profit before tax | 5 | 5 | 5 | 8 | 31 | 41 | 59 | 77 | 79 | 66 | 62 | 65 |
| Tax % | 0% | 10% | 20% | 22% | 24% | 26% | 26% | 25% | 25% | 26% | 25% | |
| Net Profit | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 59 | 49 | 47 | 49 |
| EPS in Rs | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.28 | 4.47 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 10% | 0% | 37% | 14% | 12% | 15% | 16% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 18% | 13% | 4% | 18% | ||
| Compounded Profit Growth | 26% | 9% | -7% | 9% | ||
| Stock Price CAGR | 51% | 38% | 44% | 0% | ||
| Return on Equity | 32% | 29% | 23% | 17% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 | 11 |
| Reserves | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 237 | 277 |
| Borrowings | 6 | 3 | 4 | 1 | 6 | 8 | 5 | 1 | 0 | 3 | 30 | 162 |
| Other Liabilities | 9 | 8 | 9 | 8 | 8 | 14 | 14 | 18 | 17 | 17 | 22 | 54 |
| Total Liabilities | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
| Fixed Assets | 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 | 289 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 | 121 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 | 93 |
| Total Assets | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 39 | 64 | 91 | 49 |
| Cash from Investing Activity | -0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | -55 | -112 | -172 |
| Cash from Financing Activity | -3 | -3 | -0 | -4 | 5 | 2 | -5 | -14 | -13 | -9 | 26 | 115 |
| Net Cash Flow | -1 | -0 | 0 | 1 | 0 | -0 | 3 | -4 | 6 | 0 | 5 | -9 |
| Free Cash Flow | 2 | 3 | 0 | 5 | -5 | -3 | 7 | 26 | 16 | -10 | -25 | -124 |
| CFO/OP | 44% | 73% | 57% | 99% | 25% | 24% | 51% | 94% | 81% | 107% | 156% | 78% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 24 | 71 | 26 | 52 | 87 | 59 | 80 | 44 | 58 | 76 | 134 |
| Inventory Days | 78 | 194 | 144 | 255 | 201 | 33 | 75 | 263 | ||||
| Days Payable | 947 | 240 | 84 | 145 | 131 | 99 | 218 | 625 | ||||
| Cash Conversion Cycle | 28 | 24 | 71 | -844 | 52 | 41 | 119 | 189 | 114 | -7 | -67 | -228 |
| Working Capital Days | -76 | -70 | -42 | -43 | -58 | 42 | 80 | 155 | 91 | 50 | 46 | 8 |
| ROCE % | 121% | 81% | 55% | 42% | 45% | 84% | 67% | 67% | 61% | 45% | 27% | 18% |
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.86% | 70.87% | 59.33% |
| FIIs | 0.86% | 1.05% | 1.44% | 1.49% | 1.42% | 1.91% | 2.51% | 2.95% | 1.96% | 1.80% | 1.76% | 4.93% |
| DIIs | 0.04% | 0.82% | 1.18% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 13.79% |
| Public | 28.23% | 27.26% | 26.52% | 26.47% | 26.55% | 26.05% | 25.44% | 25.01% | 26.00% | 26.15% | 26.18% | 21.95% |
| No. of Shareholders | 28,655 | 29,576 | 30,280 | 31,271 | 30,934 | 30,673 | 28,945 | 28,319 | 27,325 | 26,886 | 27,010 | 26,899 |
Fundamentals
Market Cap₹ 5,291 Cr.
Current Price₹ 406
Stock P/E109
Book Value₹ 26.4
ROCE18.1 %
ROE17.4 %
Dividend Yield0.16 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)18%
Compounded Profit Growth (TTM)9%
Standalone figures.
Valuation
Market capRs 4,160 Cr
Enterprise valueRs 4,316 Cr
P/E (TTM)85.46x
Price to book14.46x
Price to sales23.95x
EV / EBITDA50.96x
EV / EBIT61.81x
EV / sales24.84x
Price to cash flow85.29x
Earnings yield1.17%
Dividend yield0.18%
P/E, 3-year average49.46x
P/B, 3-year average10.16x
P/E, 5-year average30.50x
P/B, 5-year average6.43x
Profitability
Operating margin (excl. other income)46.09%
Operating margin (incl. other income)47.55%
EBITDA margin48.75%
Pre-tax margin37.49%
Net profit margin28.02%
Net margin, latest quarter25.28%
ROE17.41%
ROCE18.10%
ROA11.60%
ROE, 3-year average24.29%
ROCE, 3-year average30.13%
ROA, 3-year average20.27%
ROE, 5-year average33.83%
ROCE, 5-year average43.66%
ROA, 5-year average28.47%
ROIC (approx.)11.84%
Tax rate24.82%
Other income / net worth0.84%
Growth
Sales growth (latest year)9.96%
Profit growth (latest year)-4.29%
Sales CAGR, 3 years3.77%
Sales CAGR, 5 years12.86%
Profit CAGR, 3 years-6.97%
Profit CAGR, 5 years9.11%
Sales growth QoQ-0.99%
Profit growth QoQ1.65%
Sales growth YoY (latest quarter)22.08%
Profit growth YoY (latest quarter)22.19%
Per share
EPS (TTM)Rs 4.47
EPS (latest year)Rs 4.28
EPS (latest quarter)Rs 1.02
EPS, 3-year averageRs 5.63
EPS, 5-year averageRs 17.37
Book value per shareRs 26.41
Sales per shareRs 15.94
Cash flow per shareRs 4.48
Free cash flow per shareRs -11.38
Dividend per share (latest year)Rs 0.67
Dividend per share, 3-year averageRs 0.78
Dividend per share, 5-year averageRs 3.75
Dividends
Dividend payout15.64%
Dividend payout, 3-year average14.29%
Dividend payout, 5-year average18.60%
Efficiency
Asset turnover0.33x
Fixed asset turnover0.57x
Inventory turnover3.96x
Inventory days92 days
Debtor days134 days
Debtors turnover2.72x
Creditor days625 days
Cash conversion cycle-228 days
Working capital days8 days
Leverage
Total debtRs 162 Cr
Cash and bankRs 6 Cr
Net debtRs 156 Cr
Debt to equity0.56x
Net debt / EBITDA1.84x
Interest coverage14.86x
Current ratio (filing 2026-03-31)1.12x
Quick ratio (filing 2026-03-31)0.93x
Trade payables (filing 2026-03-31)Rs 37 Cr
Owners' fund to total sources57.16%
Debt to assets32.14%
Cash flow
Cash from Operating Activity (latest year)Rs 49 Cr
Cash from Investing Activity (latest year)Rs -172 Cr
Cash from Financing Activity (latest year)Rs 115 Cr
Net Cash Flow (latest year)Rs -9 Cr
Free cash flow (latest year)Rs -124 Cr
FCFE (approx.: FCF + change in debt)Rs 7 Cr
Cash from ops / profit, 5 years1.10x
Sales to cash flow3.40x
Statement figures
Net sales (TTM)Rs 174 Cr
Net sales (latest year)Rs 166 Cr
Sales (latest quarter)Rs 44 Cr
Operating profit excl. other income (latest year)Rs 76 Cr
Operating profit (latest quarter)Rs 21 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 85 Cr
PBDT (TTM)Rs 80 Cr
Profit before tax (TTM)Rs 65 Cr
Tax (latest year)Rs 15 Cr
Net profit (TTM)Rs 49 Cr
Net profit (latest year)Rs 47 Cr
Net profit (latest quarter)Rs 11 Cr
Depreciation (TTM)Rs 15 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 5 Cr
Cost of goods sold (latest year)Rs 61 Cr
Total expenditure (latest year)Rs 89 Cr
Total income (latest year)Rs 168 Cr
Share capitalRs 11 Cr
ReservesRs 277 Cr
Shareholders' fundsRs 288 Cr
Total assetsRs 503 Cr
Net blockRs 289 Cr
Capital work in progressRs 121 Cr
ReceivablesRs 61 Cr
InventoryRs 15 Cr
Other liabilitiesRs 54 Cr
Shares outstanding (crore)10.90
Ownership
Promoter holding59.33% (-11.54 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 85.5 is at the 90th percentile of its own 9.4-year range
(median 20.7, low 8.4, high 113.6).
P/B 14.46 is at the 74th percentile (median 9.22).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | GUJTHEM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -7.0% | -2.8% | -4.2 pts |
| 1 month | -9.1% | -6.8% | -2.3 pts |
| 3 months | -1.1% | -7.6% | +6.5 pts |
| 6 months | +68.3% | +0.4% | +67.9 pts |
| 1 year | -7.3% | -9.9% | +2.6 pts |
| 3 years | +179.8% | +14.2% | +165.6 pts |
| 5 years | +372.8% | +27.9% | +344.9 pts |
11 mutual fund schemes hold about ₹369 Cr.
Over three months 10 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Quant Small Cap Fund | 0.54% | 192 | +100% |
| Quant Manufacturing Fund | 5.70% | 42 | +8% |
| Bank of India Small Cap Fund | 1.08% | 36 | +100% |
| Bank of India Flexi Cap Fund | 1.01% | 30 | +100% |
| Samco Multi Asset Allocation Fund | 4.47% | 18 | +100% |
| Bank of India Mfg & Infra Fund(Q | 1.26% | 12 | +100% |
| Samco Active Momentum Fund | 1.59% | 12 | +100% |
| Bank of India Multi Cap Fund | 0.89% | 12 | +100% |
| Quant Value Fund | 0.55% | 11 | +6% |
| Quant Equity Savings Fund | 7.07% | 4 | +100% |
| Bandhan BSE Healthcare Index Fund | 0.08% | 0 | +4% |
Red flags
F-score 5 of 8| explain | Receivables outrunning sales Receivables grew 95% vs sales +10% in 2026 |
| explain | Debt up, profit down Borrowings up 431% while net profit fell in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹44 Cr +22.2% vs Jun 2025.
Net profit ₹11 Cr +22.2%.
Against our estimate for Jun 2026: sales +9.5%, profit +3.5% in line. Our estimate for Sep 2026: sales Rs 50 Cr, profit Rs 13 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-23 | Dividend - Re 0.67 Per Share | |
| 2025-09-04 | Dividend - Re 0.67 Per Share |
| Date | Type | What it says |
|---|---|---|
| 2026-10-01 | Shareholder meeting | Scrutinizers Report of 45th Annual General Meeting of the Company counter signed by the Chairman. |
| 2026-09-30 | Shareholder meeting | Voting results. |
| 2026-09-30 | Shareholder meeting | Revised outcome of 45th Annual General Meeting of the Company due to typographical error. |
| 2026-09-30 | Amendment to AOA/MOA | The Amendment to AOA/MOA of the company. |
| 2026-09-30 | Shareholder meeting | Outcome of Annual General Meeting held on September 30, 2026 |
| 2026-09-30 | Shareholder meeting | Proceedings of Annual General Meeting held on September 30, 2026 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd (GUJTHEM) has a market capitalisation of Rs 5,291 Cr. at the 2026-10-01 close.
What is the P/E ratio of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd trades at a P/E of 109 on trailing twelve-month profit, at the 2026-10-01 close.
What were Gujarat Themis Biosyn Ltd's latest quarterly results?
In the Jun 2026 quarter, Gujarat Themis Biosyn Ltd sales was Rs 44 Cr (+22.2% vs Jun 2025) and net profit was Rs 11 Cr.
What is the 52-week high and low of Gujarat Themis Biosyn Ltd?
The 52-week high is Rs 479.00 and the 52-week low is Rs 225.05.